Compare Novartis with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FRESENIUS KABI ONCO. - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FRESENIUS KABI ONCO. NOVARTIS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 856.2 22.1 3,868.9% View Chart
P/BV x 25.7 3.1 827.0% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 NOVARTIS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NOVARTIS
Mar-19
FRESENIUS KABI ONCO.
Mar-13
NOVARTIS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs980176 556.8%   
Low Rs60079 764.6%   
Sales per share (Unadj.) Rs198.737.7 527.4%  
Earnings per share (Unadj.) Rs21.05.1 411.7%  
Cash flow per share (Unadj.) Rs22.36.7 331.0%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.542.5 722.7%  
Shares outstanding (eoy) m24.69158.23 15.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.4 117.7%   
Avg P/E ratio x37.725.0 150.8%  
P/CF ratio (eoy) x35.518.9 187.6%  
Price / Book Value ratio x2.63.0 85.9%  
Dividend payout %47.70-   
Avg Mkt Cap Rs m19,50820,135 96.9%   
No. of employees `0000.61.2 50.4%   
Total wages/salary Rs m1,171703 166.5%   
Avg. sales/employee Rs Th8,445.45,176.2 163.2%   
Avg. wages/employee Rs Th2,015.7610.4 330.2%   
Avg. net profit/employee Rs Th891.0699.6 127.4%   
INCOME DATA
Net Sales Rs m4,9075,963 82.3%  
Other income Rs m78318 4,347.8%   
Total revenues Rs m5,6895,981 95.1%   
Gross profit Rs m1231,430 8.6%  
Depreciation Rs m32258 12.3%   
Interest Rs m16-26 -61.2%   
Profit before tax Rs m8581,216 70.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m340342 99.4%   
Profit after tax Rs m518806 64.2%  
Gross profit margin %2.524.0 10.4%  
Effective tax rate %39.628.1 140.9%   
Net profit margin %10.613.5 78.1%  
BALANCE SHEET DATA
Current assets Rs m8,0555,102 157.9%   
Current liabilities Rs m1,8502,385 77.6%   
Net working cap to sales %126.445.6 277.6%  
Current ratio x4.42.1 203.6%  
Inventory Days Days45150 30.0%  
Debtors Days Days34113 29.9%  
Net fixed assets Rs m1505,148 2.9%   
Share capital Rs m123158 78.0%   
"Free" reserves Rs m7,4696,556 113.9%   
Net worth Rs m7,5926,732 112.8%   
Long term debt Rs m0952 0.0%   
Total assets Rs m9,82410,388 94.6%  
Interest coverage x54.9-45.8 -120.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.6 87.0%   
Return on assets %5.47.5 72.3%  
Return on equity %6.812.0 57.0%  
Return on capital %11.514.6 78.8%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m585,298 1.1%   
Fx outflow Rs m1,3261,772 74.8%   
Net fx Rs m-1,2693,525 -36.0%   
CASH FLOW
From Operations Rs m-1,9431,274 -152.5%  
From Investments Rs m2,742-1,204 -227.7%  
From Financial Activity Rs m-298-196 152.1%  
Net Cashflow Rs m501-126 -396.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 2.0 0.3 666.7%  
FIIs % 1.6 9.6 16.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 9.1 236.3%  
Shareholders   41,647 42,599 97.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   AJANTA PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  CIPLA  TORRENT PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Moody's Downgrades India's Credit Rating, MSMEs Shut Shops, and Top Cues in Focus Today(Pre-Open)

Indian stock markets ended on a strong note yesterday. Extending gains to the fifth consecutive day, Indian stock markets edged higher.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 2, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS